NovaBridge Biosciences (NBP) Stock Forecast & Price Target

Compare

425 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBP Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

NovaBridge

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBP Stock 12 Month Forecast

Average Price Target

$8.00

▲(111.08% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for NovaBridge Biosciences in the last 3 months. The average price target is $8.00 with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 111.08% change from the last price of $3.79.

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

Highest Price Target$9.00

Average Price Target$8.00

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Zelin

BTIG

Buy

137.47%

Upside

Reiterated

01/06/26

Reiterating Buy on NovaBridge: Strong Phase 1b Givastomig Data, Manageable Safety, and Attractive Entry Point Support $9 Target

Andres Y. Maldonado

H.C. Wainwright

Buy

84.70%

Upside

Reiterated

10/27/25

Promising Clinical Data and Strategic Uncertainties: Analyst Recommends 'Buy' for I-MAB

Daina Graybosch

Leerink Partners

Buy

137.47%

Upside

Initiated

10/06/25

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), I-MAB (NASDAQ: IMAB) and Cidara Therapeutics (NASDAQ: CDTX)

Kumaraguru Raja

Brookline Capital Markets

$6→$8

Buy

111.08%

Upside

Reiterated

08/28/25

I-Mab (IMAB) PT Raised to $8 at Brookline Capital MarketsBrookline Capital Markets analyst Kumaraguru Raja raised the price target on I-Mab (NASDAQ: IMAB) to $8.00 (from $6.00) while maintaining a Buy rating.

Christopher Liu

Lucid Capital

Buy

31.93%

Upside

Initiated

05/28/25

I-Mab initiated with a Buy at Lucid CapitalI-Mab initiated with a Buy at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Zelin

BTIG

Buy

137.47%

Upside

Reiterated

01/06/26

Reiterating Buy on NovaBridge: Strong Phase 1b Givastomig Data, Manageable Safety, and Attractive Entry Point Support $9 Target

Andres Y. Maldonado

H.C. Wainwright

Buy

84.70%

Upside

Reiterated

10/27/25

Promising Clinical Data and Strategic Uncertainties: Analyst Recommends 'Buy' for I-MAB

Daina Graybosch

Leerink Partners

Buy

137.47%

Upside

Initiated

10/06/25

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), I-MAB (NASDAQ: IMAB) and Cidara Therapeutics (NASDAQ: CDTX)

Kumaraguru Raja

Brookline Capital Markets

$6→$8

Buy

111.08%

Upside

Reiterated

08/28/25

Christopher Liu

Lucid Capital

Buy

31.93%

Upside

Initiated

05/28/25

I-Mab initiated with a Buy at Lucid CapitalI-Mab initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NovaBridge Biosciences

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+13.33%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +13.33% per trade.

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+99.92%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +99.92% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

4/6 ratings generated profit

Average Return

+68.35%

reiterated a buy rating 3 months ago

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +68.35% per trade.

2 Years

xxx

Success Rate

4/6 ratings generated profit

Average Return

+68.35%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +68.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBP has received 6 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NBP average Analyst price target in the past 3 months is 8.00.

Each month's total comprises the sum of three months' worth of ratings.

NBP Financial Forecast

NBP Earnings Forecast

Next quarter’s earnings estimate for NBP is -$0.18 with a range of -$0.53 to -$0.03. The previous quarter’s EPS was -$0.06. NBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NBP has Performed in-line its overall industry.

NBP Sales Forecast

Next quarter’s sales forecast for NBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NBP has Performed in-line its overall industry.

NBP Stock Forecast FAQ

What is NBP’s average 12-month price target, according to analysts?

Based on analyst ratings, NovaBridge Biosciences’s 12-month average price target is 8.00.

What is NBP’s upside potential, based on the analysts’ average price target?

NovaBridge Biosciences has 111.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBP a Buy, Sell or Hold?

NovaBridge Biosciences has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is NovaBridge Biosciences’s price target?

The average price target for NovaBridge Biosciences is 8.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $7.00. The average price target represents 111.08% Increase from the current price of $3.79.

What do analysts say about NovaBridge Biosciences?

NovaBridge Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of NBP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NBP Analyst Ratings

NBP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NovaBridge Biosciences

NBP Analyst Recommendation Trends

NBP Financial Forecast

NBP Earnings Forecast

NBP Sales Forecast

NBP Stock Forecast FAQ

Detailed List of Analyst Forecasts